276-331-1

应用筛选条件

关键词:'276-331-1'

显示 1-5 共 5 条结果关于 "276-331-1" 范围论文

Expression, purification, characterization, and deletion mutations of phosphorylase kinase gamma subunit: identification of an inhibitory domain in the gamma subunit.

C Y Huang et al.

Molecular and cellular biochemistry, 127-128, 7-18 (1993-11-01)

A catalytic fragment, gamma 1-298, derived from limited chymotryptic digestion of phosphorylase b kinase (Harris, W.R. et al., J. Biol. Chem., 265: 11740-11745, 1990), is reported to have about six-fold greater specific activity than does the gamma subunit-calmodulin complex. To

A putative role for intramolecular regulatory mechanisms in the adaptor function of amphiphysin in endocytosis.

Khashayar Farsad et al.

Neuropharmacology, 45(6), 787-796 (2003-10-08)

Amphiphysin 1 is a brain-specific protein enriched at the synapse and a major binding partner of several components of the clathrin-mediated endocytic machinery (Proc Natl Acad Sci USA 93 (1996) 331). It interacts with clathrin-coat proteins, dynamin, and membranes (Nat

Adherence to uric acid treatment guidelines in a rheumatology clinic.

Richard Conway et al.

Clinical rheumatology, 31(12), 1707-1711 (2012-09-06)

The aim of this study was to evaluate adherence to recommended serum uric acid levels in the rheumatology outpatients department of a university teaching hospital. We performed a retrospective study of all patients with a definitive diagnosis of gout attending

T Vilsbøll et al.

The Journal of clinical endocrinology and metabolism, 88(1), 220-224 (2003-01-10)

We have previously shown that type 2 diabetic patients have decreased plasma concentrations of glucagon-like peptide 1 (GLP-1) compared with healthy subjects after ingestion of a standard mixed meal. This decrease could be caused by differences in the metabolism of

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.

Gregory J Moran et al.

The Lancet. Infectious diseases, 14(8), 696-705 (2014-06-10)

New antibiotics are needed to treat infections caused by drug-resistant bacteria. Tedizolid is a novel oxazolidinone antibacterial drug designed to provide enhanced activity against Gram-positive pathogens. We aimed to assess the efficacy and safety of intravenous to oral tedizolid for

1/1